XML 45 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 1 - Significant Accounting Policies (Details Textual) - USD ($)
shares in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 03, 2015
Nov. 06, 2013
Jun. 30, 2015
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Mar. 09, 2011
Currency Hedge Agreement [Member]                  
Collateral Already Posted, Aggregate Fair Value       $ 0   $ 0   $ 0  
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]                  
Derivative, Loss on Derivative           793,000      
Derivative, Gain on Derivative           1,654,000 $ 732,000    
JPR Royalty Sub LLC [Member]                  
Revenue Recognition Royalty and Milestone Revenue Recognized                 $ 30,000,000
Certificates of Deposit [Member]                  
Restricted Cash and Cash Equivalents, Current       150,000   150,000      
Royalty Receivable [Member]                  
Restricted Cash and Cash Equivalents, Current       70,000   70,000      
Collateral for Credit [Member]                  
Restricted Cash and Cash Equivalents       1,402,000   $ 1,402,000      
Maximum [Member]                  
Maturity Period of High Quality Marketable Securities           3 years      
Average Maturity Period of High Quality Marketable Securities           18 years      
Maturity Period of Short Term Investment           12 years      
Average Maturity for Portfolio Investments           1 year 180 days      
Minimum [Member]                  
Maturity Period of Short Term Investment           3 years      
Long-term Investment Maturity, Minimum           12 years      
CSL [Member] | Agreement [Member] | RAPIVABMember | Contingent upon EU Marketing Approval [Member]                  
Proceeds from License Fees Received     $ 7,000,000            
CSL [Member] | Agreement [Member] | RAPIVABMember | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]                  
Deferred Revenue, Additions     3,740,000            
CSL [Member] | Agreement [Member] | RAPIVABMember | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]                  
Deferred Revenue, Additions     1,223,000            
CSL [Member] | Agreement [Member] | RAPIVABMember                  
Proceeds from License Fees Received     33,740,000            
Revenues     21,777,000            
Milestone Payment Maximum     $ 12,000,000            
RAPIVABMember | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member]                  
Concentration Risk, Percentage           90.00%      
Loss on Sale of Investments           $ 0      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax           13,000 0    
Amortization of Financing Costs       110,000 $ 110,000 329,000 329,000    
Investments and Cash       119,736,000   119,736,000      
Securities Offered $ 150,000,000 $ 10,000,000              
Restricted Cash and Cash Equivalents, Current       1,622,000   1,622,000   $ 150,000  
Revenues       10,987,000 3,238,000 43,655,000 8,162,000    
Interest Expense       $ 1,241,000 $ 1,217,000 $ 3,862,000 $ 3,684,000    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount       3,821 4,240 3,673 3,986